ZIOPHARM Oncology (ZIOP) Rating Increased to Buy at BidaskClub

BidaskClub upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a report issued on Wednesday morning.

Other analysts also recently issued research reports about the stock. HC Wainwright set a $6.00 price target on shares of ZIOPHARM Oncology and gave the stock a buy rating in a research report on Tuesday, November 13th. Raymond James raised shares of ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 price target for the company in a research report on Thursday, November 15th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $5.33.

ZIOP stock opened at $3.35 on Wednesday. ZIOPHARM Oncology has a twelve month low of $1.90 and a twelve month high of $5.24. The company has a market cap of $468.43 million, a PE ratio of -6.32 and a beta of 1.85.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Research analysts expect that ZIOPHARM Oncology will post -0.51 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in ZIOP. Schwab Charles Investment Management Inc. boosted its holdings in ZIOPHARM Oncology by 7.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 713,837 shares of the biotechnology company’s stock worth $2,156,000 after purchasing an additional 49,615 shares during the period. BlackRock Inc. raised its holdings in ZIOPHARM Oncology by 8.5% during the 2nd quarter. BlackRock Inc. now owns 9,167,740 shares of the biotechnology company’s stock worth $27,686,000 after buying an additional 717,804 shares during the period. Raymond James & Associates raised its holdings in ZIOPHARM Oncology by 168.3% during the 2nd quarter. Raymond James & Associates now owns 58,290 shares of the biotechnology company’s stock worth $176,000 after buying an additional 36,568 shares during the period. Bank of America Corp DE raised its holdings in ZIOPHARM Oncology by 198.1% during the 2nd quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock worth $301,000 after buying an additional 201,063 shares during the period. Finally, Vident Investment Advisory LLC raised its holdings in ZIOPHARM Oncology by 46.8% during the 2nd quarter. Vident Investment Advisory LLC now owns 587,255 shares of the biotechnology company’s stock worth $1,774,000 after buying an additional 187,195 shares during the period. 39.95% of the stock is owned by hedge funds and other institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Read More: Correction

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit